BLAINJECTIONINJECTABLEPriority Review
Approved
Nov 2011
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
7/8 — Comprehensive
Priority Review
EYLEA (aflibercept) by Regeneron is vascular endothelial growth factor inhibitors [moa]. Approved for vascular endothelial growth factor inhibitor [epc]. First approved in 2011.
Drug data last refreshed 8h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EYLEA (aflibercept) is a fusion protein that inhibits vascular endothelial growth factor (VEGF), administered via intravitreal injection to treat neovascular age-related macular degeneration and other retinal vascular diseases. The drug works by binding VEGF and placental growth factor (PlGF), preventing abnormal blood vessel growth that causes vision loss in retinal conditions.
$0.074BPart D
PeakStable
EYLEA remains at peak commercial maturity with established market position; the brand team is stable but defending against biosimilar and next-generation competitor threats.
Mechanism of Action
Vascular Endothelial Growth Factor Inhibitors
Pharmacologic Class:
Vascular Endothelial Growth Factor Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Prospective Trial of the Efficacy and Safety of a Personalized Regimen of High-dose Aflibercept 8mg on Treatment-naive Polypoidal Choroidal Vasculopathy: the PALLAS Trial
Started Dec 2026
50 enrolled
Polypoidal Choroidal VasculopathyPolypoidal Choroidal Vasculopathy (PCV)
A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-005)
Started Sep 2026
1,104 enrolled
Diabetic RetinopathyMacular Edema
A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)
Started Aug 2026
960 enrolled
Diabetic RetinopathyMacular Edema
A Study to Evaluate the Efficacy and Safety of Tabirafusp Tedromer Compared to Aflibercept in Participants With DME - ALTO
Started Aug 2026
910 enrolled
Diabetic Macular Edema (DME)
A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration
Started May 2026
304 enrolled
Neovascular Age-related Macular DegenerationnAMD
Worked on EYLEA at Regeneron? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.